Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Contoura With Phorcides Compared to Wavefront Optimized LASIK

NCT05486546 · View on ClinicalTrials.gov ↗

Study Summary

Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.

Conditions Studied

Interventions

  • PROCEDURE Contoura with Phorcides
  • DEVICE WaveLight Wavefront Optimized

Study Locations (4)

Montana

  • Vance Thompson Vison — Bozeman

Nebraska

  • Vance Thompson Vision — Omaha

North Dakota

  • Vance Thompson Vision — Fargo

South Dakota

  • Vance Thompson Vision — Sioux Falls

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2022-08-15
Est. Completion 2023-12-01
Phase NA

Sponsor

Daniel Terveen

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05486546

The ClinicalTrials.gov registry entry for NCT05486546 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daniel Terveen, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions — of which Contoura with Phorcides is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05486546 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Montana, Nebraska, North Dakota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05486546 about?

NCT05486546 is a clinical study titled "Contoura With Phorcides Compared to Wavefront Optimized LASIK". Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.

What is the current status of trial NCT05486546?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-08-15. Estimated completion is 2023-12-01.

What conditions does trial NCT05486546 study?

This clinical trial studies the following conditions: Myopia, Astigmatism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05486546?

The interventions under investigation include: Contoura with Phorcides (PROCEDURE), WaveLight Wavefront Optimized (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05486546?

This trial is sponsored by Daniel Terveen, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05486546 being conducted?

This trial has 4 study locations across Montana, Nebraska, North Dakota, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial